Triapine and temozolomide for recurrent glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs, triapine and temozolomide, for people whose glioblastoma has come back after initial treatment. The goal is to see if this combination can help control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of brain tumor called glioblastoma that has come back after prior treatment.
- You must be at least 18 years old.
- You need to be able to have an MRI with contrast dye.
- Your general health should be good, with a Karnofsky score of 70 or higher (able to care for yourself).
- You must not be pregnant or nursing, and you must agree to use effective birth control if applicable.
- Blood and organ function tests must be within certain limits (your doctor will check these).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an experimental drug called triapine to a second round of radiation therapy can help treat brain tumors that have come back after initial treatment. It may be a good option for people with recurrent glioblastoma or astrocytoma who meet safety criteria.
This trial tests if adding a wafer (Cerebraca) placed in the brain during surgery to standard chemotherapy (temozolomide) works better than chemotherapy alone for people whose glioblastoma has come back after first treatment.
This trial tests combining two drugs, actimab-A and cemiplimab, for people whose glioblastoma has come back after prior treatment. The goal is to see if this combination can improve outcomes.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
This trial tests a combination of two drugs (niraparib and temozolomide) for people with glioblastoma or other gliomas that have come back after standard treatment. Niraparib is a type of drug that may help stop cancer cells from repairing themselves, making temozolomide work better.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
Hear when a new Recurrent Glioblastoma, IDH-Wildtype trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.